more patients on the new anticoagulant dabigatran (Pradaxa)
January 2011
You'll see more patients on the new anticoagulant dabigatran (Pradaxa)...and fewer taking warfarin for atrial fibrillation.
It's not just because dabigatran doesn't need monitoring. Dabigatran also prevents more strokes than warfarin...about 5 more strokes per 1000 patients per year...with a similar OVERALL bleeding risk.
Some insurers now cover it WITHOUT a prior authorization...and Canadian guidelines already recommend it OVER warfarin for A fib.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote